AI improves efficiency and reduces costs in clinical trials for cancer treatments
Axios · August 12, 2026Original source ↗
What happened
A study by the Tufts Center for the Study of Drug Development found that AI can accelerate the clinical development of cancer drugs by approximately 10 weeks and reduce costs by up to $5.6 million in late-stage trials. The use of AI agents can enhance patient recruitment and data management, which may allow for more clinical studies.
Why it matters
The findings suggest that AI could help streamline clinical trials and potentially improve the development process for new cancer medications.
How this story affects people
How does this story affect you if you are involved in cancer research?
The use of AI in clinical trials could streamline the process of patient recruitment and data management, potentially leading to more efficient studies and a higher rate of successful drug development.
Want this written about you?
The breakdown above is the shared version, for kinds of people. In the app, Ripple uses your job, your city, and your family, then writes that part about you.
Get your RippleMore stories
- HealthCyclospora outbreak linked to contaminated lettuce raises food safety concerns
- HealthNYC officials release documents on air quality after September 11 attacks
- HealthNew York mayor discusses asbestos exposure around Ground Zero
- HealthToxic exposure and trauma may affect brain aging in first responders at Ground Zero